Connect with us

Biotechnology

Adaptive Biotechnologies (ADPT) Soars 95% On The Debut Day

Joe Samuel

Published

on

biotech stock price

Adaptive Biotechnologies (ADPT), a Seattle based biotech company, seems to be in prime time with the booming trades under the Nasdaq. After completing its $300 million IPO, the company went public on Thursday.

ADPT stock jumped 95% above its pre IPO price of $20 per share to $39. This made the company worth $4 billion. Moreover, even the initial price had been higher than the expected $15-$17 per share.

With IPO Raised $300 Million Capital, Stocks Upped By 95% On First Trade Day

The brothers, Harlan Robins and Chad Robins who co-founded the company back in 2009. They made more history for the company by ringing the opening bell on the Nasdaq Thursday morning. This biotech IPO was the second biggest biotech IPO of 2019 being a step behind BridgeBio Pharma which had managed to raise $350 million on the same day.

Adaptive though managed to stand out with its ready-for-market products and innovative technologies. In spite of such huge successes at IPO, the overall market was still short of 28% to match up to 2018’s IPO.

Read Next : This New Technology Could Transform A Multi-Billion-Dollar Industry!

The company started by the way of Harlan Robins developing the technology and Chad Robins making a business from it. The company has come a long way forming significant partnerships with Genentech and Microsoft. In addition, it received $400 million from private investments over the last decade.

The technology helps diagnose diseases and to develop new drugs. It utilizes data based on the genetic information of the human immune system, under its ImmunoSeq platform. What’s more, is the fact that the technology has been continuously evolved keeping up with the plethora of diseases.

Deals With Microsoft and Genentech

The company in partnership with Microsoft plans to use AI to detect various diseases not taking different blood tests but making use of a single one. The announcement of the AI engine being active came forward. It’s used to help diagnose diseases like type 1 diabetes, celiac disease, lyme disease and cancers like ovarian cancer and pancreatic cancer.

Co-founder Chad Robins claimed that the product would be out in the market in 2021. With Genentech, Adaptive signed a collaborative licensing agreement worth $300 million in order to develop personalized therapy for cancer.  If it meets certain checkpoints, Adaptive Biotechnologies could be richer by almost $1.8 billion. It will receive it as a royalty payment.

The company had seen a $46.4 million of net loss against $55.6 million of revenues last year. The cash and cash equivalents stood at $440 million in the company’s balance sheet as on March 31, 2019. Before the IPO, Chad owned 6.3% of the shares of the company, while Viking Global Entities held the majority (36%). Following this Matrix Capital Management owned 16.4%. With an estimated market share worth of $48.7 billion, Adaptive became the first company in its headquartered area to go public after Avalara’s IPO in June, 2018. 

Continue Reading
Click to comment

Biotechnology

Acadia (ACAD) Stock Price is up 60% This Month; Bullish Signal For Biotechs?

Joe Samuel

Published

on

One sector that has always been a favorite of investors of all varieties is the pharmaceutical sector and all investors like a turnaround story. Over the years, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had been one of the better-known strugglers in the industry. That was reflected in the stock price as well. But recent developments have breathed new life in the stock, which could be an indicator for the biotech industry at large.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.

Acadia (ACAD) Stock Price: Important Developments

People who had held on to the stock through the barren years got a nice boost recently. This came after Acadia’s well-known medicine Nuplazid recorded better than expected sales. In addition to that, there were encouraging results from a dementia-driven psychosis study. Hence, it is important to figure out whether it is perhaps time to buy the stock.

While the signs are no doubt encouraging, it is important to note that data reveals that around 60,000 people in the United States are diagnosed with Parkinson’s every year. Out of those, a large proportion (50% to 80%) suffers from dementia. Hence it can be argued that the market is simply not too big for Acadia’s Nuplazid.

Moreover, different types of dementia are brought on by Alzheimer’s disease, which is why all of it might not actually fall into Acadia’s lap. That being said, it is also well known that antipsychotic drugs have only been approved for the treatment of Parkinson’s and hence the Alzheimer’s market is already out of the question.

Market Potential

Projections suggest that the sale of Nuplazid could grow to more than $1 billion in 2023 from $224 million in 2018. While that is encouraging, it is also important to note that the growth has been priced into the Acadia stock price.

However, if Acadia’s plans for growth somehow run into any trouble, then there is every chance of the stock price plummeting once again. The company is recovering and there is some time before the patient population for Nuplazid can be expanded sufficiently. In the meantime, investors need to be a bit more patient.

Shares of ACAD are up over 60% over the past week and made a new multi-year high of $43.98.

biotech stock price
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Biotechnology

Top Biotech Stocks To Watch This Week

Joe Samuel

Published

on

best biotech stocks to watch

Biotech stocks rarely perform well during the summer months, and 2019 has proven to be no exception in regards to this historical pattern. The iShares Nasdaq Biotechnology ETF, for example, has fallen by nearly 2% since the official start of summer.

The values of biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is that the latter part of the year is chock-full of key data readouts, regulatory decisions, and thousands of scientific conferences across the globe. 

Biotech Stocks To Watch

GT Biopharma (GTBP)

Earlier this quarter GT Biopharma, Inc. (GTBP) an immuno-oncology company focused on innovative treatments based on the Company’s proprietary NK cell engager announced that Jeffrey Miller, M.D. has been hired by the Company as its Consulting Chief Medical Officer.

Further to this, the company confirmed that it had notified FDA that it was commencing enrollment in its first-in-human GTB-3550 Phase I/II clinical trial. The clinical trial is being conducted at the University of Minnesota’s Masonic Cancer Center in Minneapolis, Minnesota under the direction of Dr. Erica Warlick.

GTB-3550 (OXS-3550) is the Company’s first Tri-specific NK cell Engager (TriKE™) product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15.

Since making the announcement, shares of GTBP are up by 13.2%.

NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corp (NASDAQ:NLNK) said the FDA has accepted partner Merck & Co., Inc. (NYSE:MRK)’s BLA for its investigational Ebola vaccine, according to the application priority review status. The PDUFA goal date has been set for March 14, 2020.

Potential approval of the vaccine will trigger issuance of a priority review voucher, owned by Merck and in which NewLink has a substantial economic interest. NewLink can then monetize its share of interest in the voucher. The vaccine candidate, originally developed by the Public Health Agency of Canada, was licensed to NewLink.

vTv Therapeutics Inc (NASDAQ:VTVT)

vTv Therapeutics Inc (NASDAQ:VTVT) is scheduled to present at the European Association for the Study of Diabetes 55th annual meeting being held in Barcelona, Spain with a new Phase 1/2 Simplici-T1 study of liver-selective glucokinase activator TTP399 as an adjunctive treatment for Type 1 diabetes.

Biotech IPO To Watch

IGM Biosciences priced its IPO of 10.938 million shares at $16, the midpoint of the estimated price range of $15-$17 per share. The shared of the preclinical and clinical-stage immuno-oncology biotech will be listed on the Nasdaq under the ticker symbol “IGMS.”

best biotech stocks to watch
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $15,000 per month for 6 months by GT Biopharma (GTBP) for a period from September 4, 2019 to March 4, 2020. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

3 Biotech Stocks Jumped Big Last Month

Joe Samuel

Published

on

biotech stocks to buy

The biotech sector has thrown up a high number of gems over the years and helped generate hefty returns for investors. Due to the advancements made in biotechnology over the years and those which are still being made, it is a sector that will continue to be a favorite of many investors.

Plenty of companies are doing revolutionary work in this space and have the potential of turning into excellent investments eventually. Here is a look at 3 biotech stocks that jumped significantly over the past few weeks and deserve to be on the watch lists of investors.

Tiziana Life Sciences (TLSA)

This biotech stock has been riding under the radar for the better part of the last 6 months. But in September, shares of Tiziana Life Sciences (TLSA) have enjoyed a much more active market. This has been due, in part to recent Phase Trial news related to the company’s pipeline therapies:

[9/16/19] Tiziana Life Sciences (TLSA) Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers

[9/10/19] Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers

[9/4/19] Tiziana Life Sciences (TLSA) Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma

Tiziana Life Sciences (TLSA) is focusing on to develop novel treatment for liver diseases such as NASH and hepatocellular carcinoma (HCC). Tiziana (TLSA) holds extensive IP and a strong pipeline of in-licensed clinical assets. Tiziana has clinical development programs for Foralumab and Milciclib. Strong IP for oral and nasal administration is for the platform technology, which is applicable to all antibodies drugs for treatment of human diseases. Click To Read More About Tiziana Life Sciences (TLSA)

Mesoblast (MESO)

The next company to watch: Mesoblast Limited (MESO Stock Report). Its shares skyrocketed last week after it emerged that it had entered into a lucrative partnership with Grunethal. Grunethal is a privately held German company. According to the terms of the deal, the companies are focusing on the development as well as sales of the product MPC-06-ID.

According to the terms of the deal, Grunethal is going to pay $15 million to Memoblast straightaway for the right to sell the medicine in South America and Europe. However, the company stands to earn as much as $135 million more if certain targets are met. The Phase 3 trials for patients in the United States are already happening and the data could be available by mid-2020.

Kodiak Science (KOD)

The other stock which made a major move last week was Kodiak Science (KOD Stock Report). The company is involved in AMD or age-related macular degeneration and similar other conditions that hamper the vision in people of advanced age.

Vision loss is one of the most important categories of treatments in the sector and there is a lot of conflict in the sector with regards to the effectiveness of anti-VEGF medicines. Kodiak is developing its own antibody known as KSI-301and recently human proof of concept data points with regards to the anti-VEGF medicine showed that the company might have actually found something that could work. That resulted in the remarkable rise in the stock price last week.

biotech stocks to watch
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Tiziana Life Sciences plc (TLSA), Midam has been paid $150,000 by Tiziana Life Sciences plc (TLSA) for a period from August 22, 2019 to September 22, 2019. We may buy or sell additional shares of Tiziana Life Sciences plc (TLSA) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Tiziana Life Sciences plc (TLSA). Full Disclaimer Click Here

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com